The Claim
Omega-3 fatty acid supplementation at a dose of 510 mg EPA and 200 mg DHA daily for six weeks is not associated with any reported adverse events in patients with advanced non-small cell lung cancer undergoing chemoradiotherapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with advanced non-small cell lung cancer receiving chemoradiotherapy, taking 510 mg EPA and 200 mg DHA daily for six weeks did not result in any reported adverse events.
See the scientific wording
Omega-3 fatty acid supplementation at a dose of 510 mg EPA and 200 mg DHA daily for six weeks is not associated with any reported adverse events in patients with advanced non-small cell lung cancer undergoing chemoradiotherapy, suggesting a favorable short-term safety profile in this population.
Omega-3 fats from supplements replace other fats in cell membranes, which changes how cells make signaling molecules. This shift reduces the production of inflammatory signals that tell the liver to make a marker called CRP and tells immune cells to release interleukin-6. Lower levels of these signals mean less overall inflammation in the body.
What the research says
1 studyThis study gave lung cancer patients a specific omega-3 supplement for six weeks while they were getting chemotherapy, and no one had any bad side effects. That means it’s likely safe to take this supplement during treatment.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.